Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Breast 2Thoracic 1

Conditions

Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 80Paclitaxel 53Trastuzumab 41Tamoxifen 40Doxorubicin 39Specimen Handling 35Docetaxel 35Magnetic Resonance Spectroscopy 34Radiotherapy 33Taxes 30Fluorouracil 26Chemotherapy, Adjuvant 26Carboplatin 24Epirubicin 22Biopsy 22Filgrastim 21Neoadjuvant Therapy 19Methotrexate 19aldesleukin 17Peripheral Blood Stem Cell Transplantation 16Bevacizumab 14Anastrozole 14exemestane 13Lapatinib 13veliparib 12CMF regimen 12sargramostim 11Goserelin 11Fulvestrant 11Capecitabine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Bexarotene × Breast × Clear all
NCT03323658 2023-01-10

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled 12 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT00003752 2013-05-30

Bexarotene in Treating Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
180 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡